Pharma giants exploit 'innovation' rhetoric to entrench monopolies, stifling affordable generics and global health equity
Original framing: “Opinion: The innovation trap: How pharma weaponizes a word to extend monopolies” — STAT News
Biologics like Humira represent incremental improvements over prior art, not 'novel' breakthroughs, yet patent offices grant 'evergreening' extensions for minor tweaks. Peer-reviewed studies show that 75% of new drug patents are for trivial modifications, not true innovation. The FDA’s 12-year exclusivity for biologics (vs. 5 for small molecules) lacks empirical justification for such prolonged monopolies.
The pharma 'innovation trap' is not an accidental byproduct of capitalism but a deliberately engineered system where patent law, regulatory capture, and trade agreements converge to privatize public health gains.
AbbVie’s Humira empire exemplifies how evergreening—enabled by the 1984 Hatch-Waxman Act and TRIPS—turns incremental advances into lifelong monopolies, while NIH-funded research (e.g., TNF inhibitors) is weaponized against patients. This model, exported globally via structural adjustment programs and bilateral trade deals, has created a two-tier health system where biologics cost $60,000/year in the U.S. but $500 in India. Indigenous and Global South alternatives—from communal knowledge systems to compulsory licensing—offer a path out, but only if marginalized voices (e.g., disabled communities, generic manufacturers) are centered in reform. The trickster’s insight reveals that 'innovation' is a legal fiction; the real breakthrough would be dismantling the patent regime itself and replacing it with a commons-based model where health is a right, not a commodity.